Generic Drug Name Capitalization
The generic drug name "warfarin" should not be capitalized when used in medical writing, prescriptions, or clinical documentation 1, 2, 3, 4, 5, 6, 7, 8.
Standard Nomenclature Practice
Throughout all major clinical guidelines and FDA labeling, warfarin is consistently written in lowercase when referring to the generic drug name 1, 2, 3, 4, 5, 6, 7. This follows standard pharmaceutical nomenclature conventions where:
- Generic (nonproprietary) drug names are written in lowercase (e.g., warfarin, apixaban, rivaroxaban)
- Brand names are capitalized (e.g., Coumadin, Jantoven)
The FDA drug label for warfarin products explicitly demonstrates this convention, with "warfarin" in lowercase throughout the prescribing information except when part of the product name "Warfarin Sodium Tablets" 9.
Clinical Documentation Standards
The International Society on Thrombosis and Haemostasis Scientific and Standardization Committee specifically recommends that anticoagulant medications be described by route of administration and specific targets, using lowercase for generic names 8. This standardization helps:
- Prevent medication errors between generic and brand-name products
- Maintain consistency across international medical literature
- Reduce confusion in prescribing and dispensing
Important Exception
The only time "Warfarin" should be capitalized is when it appears as part of an official product name (e.g., "Warfarin Sodium Tablets") or at the beginning of a sentence 9.
This lowercase convention applies universally across all clinical contexts, including prescriptions, medical records, research publications, and clinical guidelines 1, 2, 3, 4, 5, 6, 7, 8.